Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury
Information source: Canadian Network for Observational Drug Effect Studies, CNODES
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Depression; Acute Kidney Injury
Intervention: Duloxetine (Drug); Venlafaxine (Drug); Desvenlafaxine (Drug); Citalopram (Drug); Escitalopram (Drug); Fluoxetine (Drug); Fluvoxamine (Drug); Paroxetine (Drug); Sertraline (Drug)
Phase: N/A
Status: Completed
Sponsored by: Canadian Network for Observational Drug Effect Studies, CNODES Official(s) and/or principal investigator(s): Pierre Ernst, MD, MSc, Principal Investigator, Affiliation: Lady Davis Institute for Medical Research, Jewish General Hospital - McGill University
Summary
The purpose of this study is to determine if there is an excess risk of acute kidney injury
(AKI) with Serotonin-norepinephrine reuptake inhibitors (SNRIs) as compared to Selective
serotonin reuptake inhibitors (SSRIs), two classes of medication used for the treatment of
depression.
Clinical Details
Official title: Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury
Study design: Observational Model: Cohort, Time Perspective: Retrospective
Primary outcome: Acute Kidney Injury (AKI)
Detailed description:
We plan to conduct retrospective population-based cohort studies within eight administrative
databases from Canada, the United States, and the United Kingdom. Within each cohort, a
nested case-control analysis will be performed to estimate incidence rate ratios (RR) of AKI
associated with SNRIs compared to SSRIs using conditional logistic regression, with
adjustment for high-dimensional propensity scores at baseline. The overall effect across
sites will then be estimated using meta-analytic methods.
Eligibility
Minimum age: 12 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- A first prescription of an antidepressant of the SNRI or SSRI class of any dose
between January 1, 1997 and March 31, 2010.
Exclusion Criteria:
- They were <12 years old at the time of cohort entry.
- They had less than 1 year of information in the database prior to the date of cohort
entry.
- They had a prescription of an SNRI or SSRI in the year before the date of cohort
entry.
- They had a prescription for both an SNRI and an SSRI on the day of cohort entry.
- They had a history of chronic kidney disease (including kidney transplantation and
dialysis) or AKI in the year preceding cohort entry.
- The subject was previously included in the cohort.
Locations and Contacts
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec H3T1E2, Canada
Additional Information
This organization's website describing general functions, other CNODES projects, and investigator profiles.
Starting date: June 2013
Last updated: July 13, 2015
|